Novartis CEO renews commitment to Sandoz generics unit

This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEH0P0MM_L.jpg

“We remain committed to the Sandoz business,” Narasimhan said during the company’s annual results news conference, when asked about the Swiss company’s plans for the generics unit that over the years has been subject of disposal or spin-off speculation.

Novartis’s fourth-quarter results on Tuesday missed analyst forecasts. Narasimhan also announced a revamp of his digital operations, including the exit of Chief Digital Officer Bertrand Bodson.

Add Comment